2025 Q4 -tulosraportti
55 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 300 | - | - | ||
| 8 400 | - | - | ||
| 3 000 | - | - | ||
| 1 000 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sitten · MuokattuToday, John Kellum received a Bywaters Prize 2026 in Yokohama, which honors outstanding contributions to the understanding of acute kidney injury (AKI). . John Kellum is co chairman at KDIGO (there are two). So when he has stated that it is time for a paradigm shift, from the previous method to the NGAL test, it carries weight with the Committee. https://www.linkedin.com/feed/update/share:7443938896410955776/?midToken=AQHNGhjUHvGgYw&midSig=2iXSj9RgG7sYg1&trk=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D&trkEmail=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D-null-jlgqwg~mpb8nv4i~py-null-null&eid=jlgqwg-mpb8nv4i-py&otpToken=MTMwNDE2ZTQxYjJmYzljMmIwMmUwZmViNDExOWVlYjU4ZWNlZDg0NTkxYWQ4YTZlN2JjNTA2NjY0YjVkNWRmMWY3ZDNkZjllNGZjZGJkODM3MDg2ZjUxMTU0ZmMxMjNjYjg5ZDQ4NjUzZTAxZTllODFjOWIzZSwxLDE%3D
·1 päivä sittenMan, I really hope 3D is right in his prediction. Should the opposite be the case, he will have exposed himself publicly, as it happened during the SAS crash.
·1 päivä sittenAnyone who wants to chime in and tell what they think will happen with the stock on Thursday the 21st? I am new to the stock world and thought it was a cheap stock to try to invest a little in without it hurting if everything collapses.·10 t sittenAs you wrote, it's a simplified way to describe it, that's completely true, and it's the rational version. If it were that simple, there would never be any stocks that are volatile. It's important to also include the human factor, which is considered irrational. If you want to get into a stock, my best advice is that you read what has been written about the stock. You can advantageously read the "professional" analyses and you can read what is on Nordnet social, if someone has expressed an opinion about the company. If you lack inspiration, you can always click on the name, e.g. my 3D, if the person has an open account, you can see what this person has in their portfolio, and get inspiration there. ( It's a method I use when I'm looking for a new stock) Tjempman's description is correct, but there are also many other factors, and more than those I have mentioned, therefore I recommend that you read the mentioned book, because it gives you good and solid basic knowledge, and you will find it easier to navigate both written and unwritten rules. ( You will probably lose money, but as long as you earn more than you lose, then that's fine)- ·1 päivä sittenI don't think that the analysis from the preliminary financial statement has changed. https://www.sydinvest.dk/nyheder/bioporto-sigter-fortsat-mod-at-reducere-driftsunderskuddet·1 päivä sittenYes, you are right that they have sold the antibody business for approximately 67 million Danish kroner. of which approx. 62 million kr. they receive immediately and approx. 10 million which they will receive after an agreement on objectives. They have divested the business to have full focus on the NGAL test. It is no coincidence that the divestment happened at this time; it was divested because KDIGO will come with their mentioned recommendations, and because they have money to promote the NGAL test. According to the last webcast and latest article from CB. Now that we are talking about KDIGO, there has been radio silence from the committee since the hearing concluded. As long as they don't say anything, no news is good news, because then there have been no research results that have disproven that NGAL works as intended.·1 päivä sittenYou're missing my point: To refer to an older analysis that COULD ACTUALLY point to renewed capital requirements after 2026, and then call the situation unchanged! THAT IS BOTH WRONG AND STUPID - and then I don't need that "schooling" you respond to my original post with. I'm generally open to your analyses and points otherwise. But with this post, you potentially did more harm than good, as an investor who is pro BP. It means A LOT that BP rejects further capital increases before they become profitable. BP has announced that they have their financing in place until 2028. So you say: No, end of 2026! By referring to the analysis you refer to and saying that it is still valid! Regards. Bagerbrød
·14.5.Had a bit of difficulty figuring out the situation, so I used AI to go through things: https://chatgpt.com/s/t_6a057a2958f881919bc27073ee6b3157·1 päivä sittenYes, agreed, except, allegedly, that they are specifically not giving a manufacturer recommendation, but a test type recommendation. Which Bioporto can then deliver on.- ·11.5.Today is the last day regarding the hearing on AKI, and it is certain that it will not be postponed further, because otherwise they would have announced it here. https://kdigo.org/kdigo-extends-public-review-for-aki-akd-guideline-to-may-11-2026/·13.5.I admit that I have been very positive about the product NGAL test, and I still am, but I have been dissatisfied with PME's flamboyant way of being a director, which I also expressed when he was director. I have now drawn a thick line in the sand when he left BP, to focus on the management that is in place today. I am very happy with the management that is in place today, and the same applies to the board, because I believe that they are very competent to drive Bioporto forward from being a research company to a commercial company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
55 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuToday, John Kellum received a Bywaters Prize 2026 in Yokohama, which honors outstanding contributions to the understanding of acute kidney injury (AKI). . John Kellum is co chairman at KDIGO (there are two). So when he has stated that it is time for a paradigm shift, from the previous method to the NGAL test, it carries weight with the Committee. https://www.linkedin.com/feed/update/share:7443938896410955776/?midToken=AQHNGhjUHvGgYw&midSig=2iXSj9RgG7sYg1&trk=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D&trkEmail=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D-null-jlgqwg~mpb8nv4i~py-null-null&eid=jlgqwg-mpb8nv4i-py&otpToken=MTMwNDE2ZTQxYjJmYzljMmIwMmUwZmViNDExOWVlYjU4ZWNlZDg0NTkxYWQ4YTZlN2JjNTA2NjY0YjVkNWRmMWY3ZDNkZjllNGZjZGJkODM3MDg2ZjUxMTU0ZmMxMjNjYjg5ZDQ4NjUzZTAxZTllODFjOWIzZSwxLDE%3D·1 päivä sittenMan, I really hope 3D is right in his prediction. Should the opposite be the case, he will have exposed himself publicly, as it happened during the SAS crash.
- ·1 päivä sittenAnyone who wants to chime in and tell what they think will happen with the stock on Thursday the 21st? I am new to the stock world and thought it was a cheap stock to try to invest a little in without it hurting if everything collapses.·10 t sittenAs you wrote, it's a simplified way to describe it, that's completely true, and it's the rational version. If it were that simple, there would never be any stocks that are volatile. It's important to also include the human factor, which is considered irrational. If you want to get into a stock, my best advice is that you read what has been written about the stock. You can advantageously read the "professional" analyses and you can read what is on Nordnet social, if someone has expressed an opinion about the company. If you lack inspiration, you can always click on the name, e.g. my 3D, if the person has an open account, you can see what this person has in their portfolio, and get inspiration there. ( It's a method I use when I'm looking for a new stock) Tjempman's description is correct, but there are also many other factors, and more than those I have mentioned, therefore I recommend that you read the mentioned book, because it gives you good and solid basic knowledge, and you will find it easier to navigate both written and unwritten rules. ( You will probably lose money, but as long as you earn more than you lose, then that's fine)
- ·1 päivä sittenI don't think that the analysis from the preliminary financial statement has changed. https://www.sydinvest.dk/nyheder/bioporto-sigter-fortsat-mod-at-reducere-driftsunderskuddet·1 päivä sittenYes, you are right that they have sold the antibody business for approximately 67 million Danish kroner. of which approx. 62 million kr. they receive immediately and approx. 10 million which they will receive after an agreement on objectives. They have divested the business to have full focus on the NGAL test. It is no coincidence that the divestment happened at this time; it was divested because KDIGO will come with their mentioned recommendations, and because they have money to promote the NGAL test. According to the last webcast and latest article from CB. Now that we are talking about KDIGO, there has been radio silence from the committee since the hearing concluded. As long as they don't say anything, no news is good news, because then there have been no research results that have disproven that NGAL works as intended.·1 päivä sittenYou're missing my point: To refer to an older analysis that COULD ACTUALLY point to renewed capital requirements after 2026, and then call the situation unchanged! THAT IS BOTH WRONG AND STUPID - and then I don't need that "schooling" you respond to my original post with. I'm generally open to your analyses and points otherwise. But with this post, you potentially did more harm than good, as an investor who is pro BP. It means A LOT that BP rejects further capital increases before they become profitable. BP has announced that they have their financing in place until 2028. So you say: No, end of 2026! By referring to the analysis you refer to and saying that it is still valid! Regards. Bagerbrød
- ·14.5.Had a bit of difficulty figuring out the situation, so I used AI to go through things: https://chatgpt.com/s/t_6a057a2958f881919bc27073ee6b3157·1 päivä sittenYes, agreed, except, allegedly, that they are specifically not giving a manufacturer recommendation, but a test type recommendation. Which Bioporto can then deliver on.
- ·11.5.Today is the last day regarding the hearing on AKI, and it is certain that it will not be postponed further, because otherwise they would have announced it here. https://kdigo.org/kdigo-extends-public-review-for-aki-akd-guideline-to-may-11-2026/·13.5.I admit that I have been very positive about the product NGAL test, and I still am, but I have been dissatisfied with PME's flamboyant way of being a director, which I also expressed when he was director. I have now drawn a thick line in the sand when he left BP, to focus on the management that is in place today. I am very happy with the management that is in place today, and the same applies to the board, because I believe that they are very competent to drive Bioporto forward from being a research company to a commercial company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 300 | - | - | ||
| 8 400 | - | - | ||
| 3 000 | - | - | ||
| 1 000 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
55 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuToday, John Kellum received a Bywaters Prize 2026 in Yokohama, which honors outstanding contributions to the understanding of acute kidney injury (AKI). . John Kellum is co chairman at KDIGO (there are two). So when he has stated that it is time for a paradigm shift, from the previous method to the NGAL test, it carries weight with the Committee. https://www.linkedin.com/feed/update/share:7443938896410955776/?midToken=AQHNGhjUHvGgYw&midSig=2iXSj9RgG7sYg1&trk=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D&trkEmail=eml-email_next_best_action_digest_01-zwzCWIomQlCY80z4%2FH1i8g%3D%3D-0-lHbvaMJdjxRIBLQMvKaQVA%3D%3D-null-jlgqwg~mpb8nv4i~py-null-null&eid=jlgqwg-mpb8nv4i-py&otpToken=MTMwNDE2ZTQxYjJmYzljMmIwMmUwZmViNDExOWVlYjU4ZWNlZDg0NTkxYWQ4YTZlN2JjNTA2NjY0YjVkNWRmMWY3ZDNkZjllNGZjZGJkODM3MDg2ZjUxMTU0ZmMxMjNjYjg5ZDQ4NjUzZTAxZTllODFjOWIzZSwxLDE%3D·1 päivä sittenMan, I really hope 3D is right in his prediction. Should the opposite be the case, he will have exposed himself publicly, as it happened during the SAS crash.
- ·1 päivä sittenAnyone who wants to chime in and tell what they think will happen with the stock on Thursday the 21st? I am new to the stock world and thought it was a cheap stock to try to invest a little in without it hurting if everything collapses.·10 t sittenAs you wrote, it's a simplified way to describe it, that's completely true, and it's the rational version. If it were that simple, there would never be any stocks that are volatile. It's important to also include the human factor, which is considered irrational. If you want to get into a stock, my best advice is that you read what has been written about the stock. You can advantageously read the "professional" analyses and you can read what is on Nordnet social, if someone has expressed an opinion about the company. If you lack inspiration, you can always click on the name, e.g. my 3D, if the person has an open account, you can see what this person has in their portfolio, and get inspiration there. ( It's a method I use when I'm looking for a new stock) Tjempman's description is correct, but there are also many other factors, and more than those I have mentioned, therefore I recommend that you read the mentioned book, because it gives you good and solid basic knowledge, and you will find it easier to navigate both written and unwritten rules. ( You will probably lose money, but as long as you earn more than you lose, then that's fine)
- ·1 päivä sittenI don't think that the analysis from the preliminary financial statement has changed. https://www.sydinvest.dk/nyheder/bioporto-sigter-fortsat-mod-at-reducere-driftsunderskuddet·1 päivä sittenYes, you are right that they have sold the antibody business for approximately 67 million Danish kroner. of which approx. 62 million kr. they receive immediately and approx. 10 million which they will receive after an agreement on objectives. They have divested the business to have full focus on the NGAL test. It is no coincidence that the divestment happened at this time; it was divested because KDIGO will come with their mentioned recommendations, and because they have money to promote the NGAL test. According to the last webcast and latest article from CB. Now that we are talking about KDIGO, there has been radio silence from the committee since the hearing concluded. As long as they don't say anything, no news is good news, because then there have been no research results that have disproven that NGAL works as intended.·1 päivä sittenYou're missing my point: To refer to an older analysis that COULD ACTUALLY point to renewed capital requirements after 2026, and then call the situation unchanged! THAT IS BOTH WRONG AND STUPID - and then I don't need that "schooling" you respond to my original post with. I'm generally open to your analyses and points otherwise. But with this post, you potentially did more harm than good, as an investor who is pro BP. It means A LOT that BP rejects further capital increases before they become profitable. BP has announced that they have their financing in place until 2028. So you say: No, end of 2026! By referring to the analysis you refer to and saying that it is still valid! Regards. Bagerbrød
- ·14.5.Had a bit of difficulty figuring out the situation, so I used AI to go through things: https://chatgpt.com/s/t_6a057a2958f881919bc27073ee6b3157·1 päivä sittenYes, agreed, except, allegedly, that they are specifically not giving a manufacturer recommendation, but a test type recommendation. Which Bioporto can then deliver on.
- ·11.5.Today is the last day regarding the hearing on AKI, and it is certain that it will not be postponed further, because otherwise they would have announced it here. https://kdigo.org/kdigo-extends-public-review-for-aki-akd-guideline-to-may-11-2026/·13.5.I admit that I have been very positive about the product NGAL test, and I still am, but I have been dissatisfied with PME's flamboyant way of being a director, which I also expressed when he was director. I have now drawn a thick line in the sand when he left BP, to focus on the management that is in place today. I am very happy with the management that is in place today, and the same applies to the board, because I believe that they are very competent to drive Bioporto forward from being a research company to a commercial company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 300 | - | - | ||
| 8 400 | - | - | ||
| 3 000 | - | - | ||
| 1 000 | - | - | ||
| 5 000 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt